Skip to main content
Market snapshot: . Prices may have changed since this snapshot.
Events
GroupKALSHI
Will the FDA approve CagriSema?
Will the FDA approve CagriSema?
Reported volume
K 7.1K contracts
Events
1
Markets
3

Current odds

Snapshot from

As of Nov 22, 2026, 12:00 PM UTC, the highest-priced outcome on Kalshi is Before Jan 1, 2027 at 96.5%.

Kalshi

  1. Before Jan 1, 202796.5%
  2. Before Jan 1, 202893%
  3. Before Jul 1, 202792%

Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.

AI Analysis

Trader mode: Market mechanics, assumptions and risks

K 7.1K contracts

Reported volume · provider units

3

Saved contracts

0

Same-question pairs

Source snapshot: Nov 22, 2026, 12:00 PM UTC

Snapshot observed Nov 21, 2026, 3:00 PM UTC. This analysis describes that snapshot and is not a live news update.

What the contract measures

The Kalshi event asks whether the FDA will approve CagriSema. Under the rules, a market resolves Yes if the FDA approves CagriSema for marketing before the stated deadline. For new drugs, approval means issuance of an approval letter for an NDA or BLA, and standard, accelerated, REMS, and restricted-distribution approvals count [1]. Complete Response Letters, approvable letters, requests for more information, and Emergency Use Authorization without full approval do not count [1]. The rules also say a market resolves No if the sponsor withdraws the application before FDA action and before the deadline [1]. The wording matters: a CRL followed by a later approval before the deadline can still resolve Yes [1].

Three markets share this event but have different deadlines: before January 1, 2027, before July 1, 2027, and before January 1, 2028. Their listed end times are Jan 1, 2027, 4:59 AM UTC, Jul 1, 2027, 3:59 AM UTC, and Jan 1, 2028, 4:59 AM UTC [1]. These are contract closing times, not announced FDA dates.

Reading the snapshot

The provider observation time is Nov 21, 2026, 3:00 PM UTC, and the source was retrieved at Nov 21, 2026, 4:22 PM UTC [1]. This is a record of those moments, not a live quote. The quoted Yes prices were 0.95 for the January 2027 deadline, 0.905 for July 2027, and 0.93 for January 2028. The matching No prices were 0.05, 0.095, and 0.07. The July 2027 Yes price is lower than the January 2028 price, so the prices do not rise steadily with the deadline. The evidence does not explain this. These are snapshot prices, not executable quotes or verified probabilities.

All three saved Kalshi markets are included, and the sample is not flagged as partial. The reported volume is 7,125 contracts. That is the provider's own total in its own units, and it does not indicate liquidity or the number of traders.

What remains uncertain

The evidence does not include an event-level end time, the current FDA review status, or any related news. It also does not establish that the provider lists every possible outcome. Only one source supports these terms, and no other platform's prices are included, so no cross-platform comparison is possible. Differences between these three deadline contracts reflect different wording and closing times, not an arbitrage opportunity.

References

  1. Kalshi: Will the FDA approve CagriSema?. Provider data observed Nov 21, 2026, 3:00 PM UTC.

AI-generated analysis based on market data. Not financial advice.

Saved Nov 21, 2026 UTC

Overview

This PredictPedia entry covers a Kalshi event asking whether the U.S. Food and Drug Administration (FDA) will approve CagriSema. The contract resolves to Yes if the FDA approves CagriSema for marketing before the deadline in a given market [1]. Approval is defined by type of application. For new drugs, it means the FDA issues an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA). For drugs already on the market seeking a new indication, it means approval of a supplemental NDA or supplemental BLA for the specific indication named. Generic drugs and biosimilars are covered by their own application types [1]. The rules count standard approvals, accelerated approvals based on surrogate endpoints, and approvals with a Risk Evaluation and Mitigation Strategy (REMS) or restricted distribution or indication limits. Compassionate use or expanded access programs alone do not count [1]. The rules also list several outcomes that do not count as approval. These include Complete Response Letters (CRLs), approvable letters that require further action, tentative approvals tied to patent or exclusivity expiration, requests for more information or studies, extensions of user fee dates, and Emergency Use Authorizations without full approval [1]. The event contains three markets with different deadlines: January 1, 2027, July 1, 2027, and January 1, 2028 [1]. The saved snapshot shows the January 1, 2027 market with a Yes price of 0.95 and a No price of 0.05, the January 1, 2028 market at 0.93 Yes and 0.07 No, and the July 1, 2027 market at 0.905 Yes and 0.095 No. These figures were observed at 2026-11-21T15:00:06Z and retrieved in the saved record at 16:22 UTC on the same day. They describe that snapshot only. They are not live prices, executable quotes, or verified probabilities. All three markets in the saved event are included, so this is the full set of markets the provider reported for this event, though that does not establish that every possible outcome is listed. Kalshi reports a total of 7,125 contracts traded for this event [1]. That figure is the provider's own event total in contracts. It does not measure liquidity or the number of traders.

Why It Matters

The contract measures whether a specific regulatory action, FDA approval of CagriSema for marketing, occurs before a stated deadline [1]. Because the rules separate formal approval from outcomes such as a Complete Response Letter or an Emergency Use Authorization, the wording of the approval definition controls resolution. Traders reading the Yes price should note the deadline attached to each market, since the three markets in this event ask the same approval question with different end dates [1]. The rules also state that a market closes early if the event occurs [1].

Snapshot context

The latest published provider snapshot for this topic was observed on 2026-11-21 at 15:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]

Frequently Asked Questions

What counts as an approval under this contract?

An approval includes FDA issuance of an approval letter for a new NDA or BLA, FDA approval of a supplemental NDA or BLA for a referenced indication, and approvals that are standard, accelerated, include a REMS, or carry restricted distribution or indication limits, excluding compassionate use or expanded access [1].

Does a Complete Response Letter resolve the market to Yes?

No. The rules state that a Complete Response Letter indicates the application cannot be approved in its current form and does not count as an approval. Under the rules, the market resolves to No if the FDA issues a CRL before the deadline, unless the FDA later approves CagriSema after addressing the CRL concerns and before the deadline [1].

What happens if the FDA holds an advisory committee vote against approval?

The rules state that if an advisory committee votes against approval but the FDA approves CagriSema anyway before the deadline, the market resolves to Yes [1].

What happens if an accelerated approval is later withdrawn?

According to the rules, the market resolves based on whether the initial accelerated approval occurred before the deadline. A later withdrawal does not change that result [1].

What happens if the sponsor withdraws the application before FDA action?

The rules state that if the drug sponsor withdraws the application before FDA action and before the deadline, the market resolves to No immediately, and the market closes early [1].

Does the Kalshi volume figure show how liquid these markets are?

No. The reported total of 7,125 contracts is the provider's own event total in its own units. It does not establish liquidity or the number of participants [1].

Was this helpful?
Saved Nov 21, 2026 UTC

AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.

Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

KalshiHealth
Will the FDA approve MDMA for PTSD?

Will the FDA approve MDMA for PTSD?

K 13.7K contracts
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?Yes 54%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?Yes 53%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2029?Yes 52%
+3 moreNext deadline Jan 1, 2027 UTC
KalshiHealth
Will the FDA approve VERVE-102?

Will the FDA approve VERVE-102?

K 1.8K contracts
Will the FDA approve VERVE-102 before Jan 1, 2035?Yes 83.5%
Will the FDA approve VERVE-102 before Jan 1, 2034?Yes 77.5%
Will the FDA approve VERVE-102 before Jan 1, 2033?Yes 75.5%
+3 moreNext deadline Jan 1, 2030 UTC
PolymarketKalshiScience
Will the FDA approve retatrutide?

Will the FDA approve retatrutide?

PM $599.3K · K 121.2K contracts

FDA approves Retatrutide this year?

Kalshi: When will the FDA approve retatrutide (LY3437943)? (Before Jan 1, 2027)

Same question, fine print differs

PM Yes 1.3%Rules differK Yes 1.5%

Related or unreviewed contracts may settle differently. Their gap is not an equivalent-contract comparison.

Saved prices; check contract rules.

1 saved comparisonNext deadline Jan 1, 2027 UTC
KalshiHealth
When will the FDA approve Compass Pathways' COMP360 Psilocybin?

When will the FDA approve Compass Pathways' COMP360 Psilocybin?

K 28.1K contracts
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before 2028)Yes 90.5%
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before October 2027)Yes 88%
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before July 2027)Yes 83.5%
+2 moreNext deadline Jan 1, 2027 UTC
KalshiHealth
Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

K 3.2K contracts
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?Yes 95%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?Yes 85.5%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?Yes 64.5%
+2 moreNext deadline Apr 1, 2027 UTC
KalshiHealth
When will the FDA approve Intellia Therapeutics' lonvo-z?

When will the FDA approve Intellia Therapeutics' lonvo-z?

K 6.6K contracts
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)Yes 92.5%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)Yes 92%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)Yes 89%
3 mktsNext deadline Jul 1, 2027 UTC

Market Insights

Price gaps of 2 pp+

0

Same-question pairs

0

No outcomes on this page have been reviewed as the same question on both platforms yet.

Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.

Trade This Market